Nicole F Maranchick,
Pharmacist
Department:
Pharmacotherapy & Translational Research
Business Phone:
(352) 273-6803
Business Email:
n.maranchick@ufl.edu
Publications
Academic Articles
2024
Association of piperacillin and vancomycin exposure on acute kidney injury during combination therapy.
JAC-antimicrobial resistance.
6(1)
[DOI] 10.1093/jacamr/dlad157.
[PMID] 38259903.
2024
Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics
Expert Review of Clinical Pharmacology.
17(7):537-547
[DOI] 10.1080/17512433.2024.2317954.
[PMID] 38339997.
2024
Early vigabatrin to augment GABAergic pathways in post-anoxic status epilepticus.
Epilepsy & behavior : E&B.
160
[DOI] 10.1016/j.yebeh.2024.110082.
[PMID] 39393141.
2024
Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.
36
[DOI] 10.1016/j.jctube.2024.100444.
[PMID] 38708036.
2023
A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia
Therapeutic Drug Monitoring.
46(1):95-101
[DOI] 10.1097/ftd.0000000000001144.
[PMID] 38018847.
2023
Adequacy of WHO weight-band dosing and fixed-dose combinations for the treatment of TB in children.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
27(5):401-407
[DOI] 10.5588/ijtld.22.0591.
[PMID] 37143230.
2023
Beta-lactam target attainment and associated outcomes in patients with bloodstream infections
International Journal of Antimicrobial Agents.
61(3)
[DOI] 10.1016/j.ijantimicag.2023.106727.
[PMID] 36646230.
2023
Cefepime Daily Exposure and the Associated Impact on the Change in Sequential Organ Failure Assessment Scores and Vasopressors Requirement in Critically Ill Patients Using Repeated-Measures Mixed-Effect Modeling
Critical Care Explorations.
5(11)
[DOI] 10.1097/cce.0000000000000993.
[PMID] 38304706.
2023
Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children
The International Journal of Tuberculosis and Lung Disease.
27(12):931-937
[DOI] 10.5588/ijtld.23.0184.
[PMID] 38042977.
2023
Impact of Beta-Lactam Target Attainment on Resistance Development in Patients with Gram-Negative Infections
Antibiotics.
12(12)
[DOI] 10.3390/antibiotics12121696.
[PMID] 38136730.
2023
Making the case for precision dosing: visualizing the variability of cefepime exposures in critically ill adults.
The Journal of antimicrobial chemotherapy.
78(9):2170-2174
[DOI] 10.1093/jac/dkad211.
[PMID] 37449472.
2023
Pharmacokinetics and pharmacodynamics of adult dolutegravir tablets in treatment-experienced children with HIV weighing at least 20 kg
AIDS.
Publish Ahead of Print(9):1409-1417
[DOI] 10.1097/qad.0000000000003576.
[PMID] 37070558.
2023
The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation
International Journal of Antimicrobial Agents.
62(4)
[DOI] 10.1016/j.ijantimicag.2023.106939.
[PMID] 37517627.
2022
Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis.
Frontiers in pharmacology.
13
[DOI] 10.3389/fphar.2022.1048653.
[PMID] 36578553.
2022
Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue.
Antimicrobial agents and chemotherapy.
66(8)
[DOI] 10.1128/aac.00438-22.
[PMID] 35862739.
2022
Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity.
Pharmacotherapy.
43(1):6-14
[DOI] 10.1002/phar.2744.
[PMID] 36401796.
2022
Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia.
Antimicrobial agents and chemotherapy.
66(7)
[DOI] 10.1128/aac.00563-22.
[PMID] 35699444.
Grants
Aug 2024
ACTIVE
Addressing Research Gaps to Optimize Dolutegravir-based ART in Children and Adolescents
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Contact Details
Phones:
- Business:
- (352) 273-6803
Emails:
- Business:
- n.maranchick@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100486
GAINESVILLE FL 32610 - Business Street:
-
1600 SW ARCHER RD
GAINESVILLE FL 32610